Treatment of Netherton syndrome with upadacitinib
Clinical and Experimental Dermatology · 16.11.2023 · 48 (12) · 1379-1381
DOI: 10.1093/ced/llad242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 21.07.2023. Verfasst von Xinyu Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, 1st Hospital of Jilin University, Changchun city, Jilin Province, China. Hauptthemen laut MEDLINE: Netherton Syndrome, Ichthyosiform Erythroderma, Congenital. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
We reported the case of a patient with Netherton syndrome (NS) who showed remarkable cutaneous improvement using upadacitinib in the short term, but the efficacy decreased long term. This patient’s case demonstrates that Janus kinase inhibitors have reduced long-term clinical efficacy, which is the same as other biologic therapies used to treat patients with NS. This shows that NS is a complex skin disorder and more studies and clinical trials are required focusing on the long-term efficacy of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, 1st Hospital of Jilin University, Changchun city, Jilin Province, China.
ORCID-Profile: Bing Han
Zitieren
APA
Li, X., Han, B., & Li, S. (2023). Treatment of Netherton syndrome with upadacitinib. Clinical and Experimental Dermatology, 48(12), 1379-1381. https://doi.org/10.1093/ced/llad242
Vancouver
Li X, Han B, Li S. Treatment of Netherton syndrome with upadacitinib. Clinical and Experimental Dermatology. 2023;48(12):1379-1381. doi:10.1093/ced/llad242
BibTeX
@article{Li2023,
author = {Li, Xinyu and Han, Bing and Li, Shanshan},
title = {Treatment of Netherton syndrome with upadacitinib},
journal = {Clinical and Experimental Dermatology},
year = {2023},
volume = {48},
number = {12},
pages = {1379--1381},
doi = {10.1093/ced/llad242}
}
EUVIMED